DESTRUXIN B

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H51N5O7
Molecular Weight	593.7552
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CC(C)C)OC(=O)CCNC(=O)[C@H](C)N(C)C(=O)[C@H](C(C)C)N(C)C1=O

InChI

InChIKey=GNBHVMBELHWUIF-VTSYCQLTSA-N

InChI=1S/C30H51N5O7/c1-10-19(6)24-29(40)34(9)25(18(4)5)30(41)33(8)20(7)26(37)31-14-13-23(36)42-22(16-17(2)3)28(39)35-15-11-12-21(35)27(38)32-24/h17-22,24-25H,10-16H2,1-9H3,(H,31,37)(H,32,38)/t19-,20-,21-,22+,24-,25-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C30H51N5O7
Molecular Weight	593.7552
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22753733
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24204395 | https://www.ncbi.nlm.nih.gov/pubmed/7802670

Destruxin B, isolated from entomopathogenic fungus Metarhizium anisopliae, is one of the cyclodepsipeptides with antimicrobial, insecticidal and anticancer activities. Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vacuolar H(+)-ATPase 1 Target ID: CHEMBL4798 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7802670	Inhibitor 8504		5.4 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 609 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22753733	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Destruxin B Isolated from Entomopathogenic Fungus Metarhizium anisopliae Induces Apoptosis via a Bcl-2 Family-Dependent Mitochondrial Pathway in Human Nonsmall Cell Lung Cancer Cells.	2013	24204395
Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase.	1994-12-15	7802670

Patents

Sample Use Guides

In Vivo Use Guide

The anticancer effects of DB were investigated in a murine xenograft model of human colon cancer (CRC). Destruxin B administered subcutaneously daily at 0.6-15 mg/kg was proven to be safe and effective in inhibiting the growth of CRC cells.

Route of Administration: Other

In Vitro Use Guide

The human lung cancer A549 and H1299 cells were treated with various concentrations of destruxin B (0, 1, 5, 10, 20, and 30 mkM) for 48h. After treatment, the number of viable cells was determined by trypan-blue dye exclusion method.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 13:30:01 GMT 2025` Edited by `admin` on `Wed Apr 02 13:30:01 GMT 2025`
Record UNII	7R6CR62KFE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NSC-236580

Preferred Name

English

DESTRUXIN B

Common Name

English

CYCLO(N-METHYL-L-ALANYL-.BETA.-ALANYL-(2R)-2-HYDROXY-4-METHYLPENTANOYL-L-PROLYL-L-ISOLEUCYL-N-METHYL-L-VALYL)

Systematic Name

English

SB-242536

Code

English

PYRROLO(1,2-D)(1,4,7,10,13,16)OXAPENTAAZACYCLONONADECINE-1,4,7,10,14,17(11H,16H)-HEXONE, 3-SEC-BUTYLDODECAHYDRO-16-ISOBUTYL-6-ISOPROPYL-5,8,9-TRIMETHYL-

Systematic Name

English

Code System Code Type Description

FDA UNII

7R6CR62KFE